Differential Expression of Cell Cycle Regulatory Molecules and Evidence for a "Cyclin Switch" during Progression of Prostate Cancer

Prostate

Volumn 58, Issue 4, 2004, Pages 335-344

  Maddison, Lisette A ^a   Huss, Wendy J ^a   Barrios, Roberto M ^a   Greenberg, Norman M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cell cycle; Cyclins; Prostate cancer; TRAMP

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLINE;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CELL CYCLE; CYCLIN-DEPENDENT KINASES; CYCLINS; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; REFERENCE VALUES; SERINE ENDOPEPTIDASES;

EID: 1542377562     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10341     Document Type: Article

References (25)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998;35:95-101.
3. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891-1895.
4. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 1996;56:4159-4163.
5. Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate 1999;38:175-182.
6. Kallakury, BV, Sheehan CE, Rhee SJ, Fisher HA, Kaufman RP Jr., Rifkin MD, Ross JS. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 1999;85:1569-1576.
7. Greenberg N, DeMayo F, Finegold M, Medina D, Tilley W, Aspinall J, Cunha G, Donjacour A, Matusik R, Rosen J. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
8. Sharma P, Schreiber AN. Mouse models of prostate cancer. Oncogene 1999;18:5349-5355.
9. Abate-Shen C, Shen MM. Mouse models of prostate carcinogenesis. Trends Genet 2002;18:S1-S5.
10. Bodmer WF. Prostate cancer 2000. Prostate Cancer Prostatic Dis 2000;3:218-223.
11. Kaplan-Lefko PJ, Chen T-M, Ittmann M, Barrios RS, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2002 (in press).
12. Gingrich J, Barrios R, Foster B, Greenberg N. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer and Prostatic Dis 1999;2:70-75.
13. Gingrich J, Barrios R, Kattan M, Nahm H, Finegold M, Greenberg N. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-4691.
14. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203-2209.
15. Foster BA, Kaplan PJ, Greenberg NM. Characterization of the FGF axis and identification of a novel FGFR1 iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:76-82.
16. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 2001;276:11204-11213.
17. Wechter WJ, Leipold DD, Murray ED Jr., Quiggle D, McCracken JD, Barrios RS, Greenberg NM. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000;60:2203-2208.
18. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-2448.
19. Chapman DL, Wolgemuth DJ. Isolation of the murine cyclin B2 cDNA and characterization of the lineage and temporal specificity of expression of the B1 and B2 cyclins during oogenesis, spermatogenesis, and early embryogenesis. Development 1993;118:229-240.
20. Muller-Tidow C, Bornemann C, Diederichs S, Westermann A, Klumpen S, Zuo P, Wang W, Berdel WE, Serve H. Analyses of the genomic methylation status of the human cyclin A1 promoter by a novel real-time PCR-based methodology. FEBS Lett 2001;490:75-78.
21. Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E. Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 1996;12:2631-2640.
22. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-3511.
23. Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, Zuckerman KS. Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem 2002;277:16528-16537.
24. Knudsen K, Cavenee W, Arden K. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 1999;59:2297-2301.
25. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin Dl nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000;14:3102-3114.